Programs Designed to Address Unmet Needs in Bacterial Infections and Rare Diseases

Spero Therapeutics’ antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal.

Our pipeline of anti-infective agents is one of the most unique in the industry and consists of three investigational product candidates, including:

• Tebipenem HBr, an oral carbapenem that completed a pivotal Phase 3 clinical trial, ADAPT-PO, for the treatment of complicated urinary tract infections and acute pyelonephritis. If approved, tebipenem HBr will be a novel oral formulation of tebipenem, a carbapenem-class antibiotic marketed in Japan since 2009 for specific pediatric infections.  
• SPR720, an oral antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial (NTM) lung disease.
• SPR206, a direct acting intravenous (IV)-administered next-generation polymyxin analogue developed from our potentiator platform that is in clinical development as an innovative potential option to treat MDR Gram-negative bacterial infections within the hospital. 

The following table illustrates our product candidates, their status, and anticipated milestones for ongoing development.

Information as of July 8, 2022

This chart contains forward-looking statements. Our planned development activities and anticipated milestones are based on our current assumptions, estimates, and plans, which may change.